Pfizer has announced a deal with AstraZeneca for exclusive over-the-counter (OTC) rights to market Nexium for approved indications in the United States, Europe and the rest of the world.

AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for an upfront payment of $922 million. The move represents the biggest single investment to date ...

Ranbaxy and AstraZeneca have been embroiled in legal action since 2005 over Ranbaxy’s intention to market a generic version of Nexium. Ranbaxy received a tentative approval from the US Food and ...